Zai Lab, Ltd.
Zai Lab, Ltd. is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
Zai Lab has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on an extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late-stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. Zai Lab is further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year.
Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing, and commercializing innovative medicines. To that end, it has built its internal R&D center to advance the discovery pipeline, a strong clinical development and operations team, and its own manufacturing facilities in China. Zai Lab has also established a highly specialized commercial team to support marketing of its innovative products in China. Zai Lab believes this integrated approach will provide sustainable competitive advantages.
Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017 and completed secondary listing on Hong Kong Stock Exchange in September 2020. Zai Lab significantly expanded with several offices across China and U.S. and opened its U.S. headquarters in San Francisco in December 2018. As of September 2020, Zai Lab has a global team of over 900 employees.
Location of Key Operations
Deloitte Touche Tohmatsu CPA LLP
IPO (September 20, 2017)
Shanghai, Beijing, Guangzhou, Suzhou, HK, Taiwan, Cambridge, San Francisco
Billy Cho, Internal
Credit Suisse, Citi, Haitong, Guggenheim, Bank of America/Merril Lynch, Jefferies, CICC, JPM, BOCI, LEERINK, Macquirie, China Renaissance, Goldman Sachs
September 21, 2021: Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer | Zai Lab Limited (zailaboratory.com)
September 15, 2021: Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer | Zai Lab Limited (zailaboratory.com)
June 25, 2021: Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation | Zai Lab Limited (zailaboratory.com)
June 21, 2021: argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology | Zai Lab Limited (zailaboratory.com)
May 24, 2021: Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer | Zai Lab Limited (zailaboratory.com)
April 22, 2021: OVERSEAS REGULATORY ANNOUNCEMENT
February 19, 2021: Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
January 11, 2021: Turning Point and Zai Lab Broaden Collaboration